Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Crypto’s Biggest Phase Has Begun: 5 Altcoins Worth Buying as the Fed Decision Shapes the Next Bull Run

Crypto’s Biggest Phase Has Begun: 5 Altcoins Worth Buying as the Fed Decision Shapes the Next Bull Run

CryptonewslandCryptonewsland2026/07/31 23:48
By:Cryptonewsland
  • The Fed decision is influencing crypto sentiment, with investors closely watching liquidity and risk appetite.
  • Solana, Tezos, LayerZero, and Uniswap continue expanding through ecosystem growth and blockchain development.
  • SPX6900 remains a high-volatility asset, attracting speculative interest alongside established altcoins.

The recent Federal Reserve interest rate decision has been one of the top events being monitored in the financial markets, including in digital assets. In the second half of the year, market participants have continued to evaluate the impact possible future monetary policy will have on liquidity, investor confidence, and investor appetite for risk. 

Macroeconomic indicators can influence the direction of money flows into higher-risk assets, as cryptocurrencies have had their ups and downs lately, according to analysts. Generally, a stable interest rate outlook has been considered to be supportive for digital assets as the borrowing conditions are stable and investors are inclined to provide more funds to the growth areas. While more people turn their focus away from Bitcoin, several other altcoins have received newfound interest thanks to their continuous development, widening of ecosystems, and adoption in the fields of decentralized finance, infrastructure, and digital applications. 

Solana Maintains Strong Network Activity

Solana (SOL) has managed to stay one of the top blockchain networks. The network has been expanding into the decentralized finance space as well as payments, gaming, and tokenized assets. Analysts have noted that the efficiency of transactions and growth in the participation of the ecosystem have led to a sustained focus on the market despite the wider market movements.

Tezos Focuses on Long-Term Development

Tezos (XTZ) has been continuing to stress its network developments with the help of its self-amending blockchain design. It has been continuously developed, and smart contracts and decentralized applications have been supported. Institutional blockchain projects and enterprise solutions that are ongoing in search of Tezos have also been cited by market participants as a reason.

LayerZero Expands Cross-Chain Infrastructure

LayerZero (ZRO) has gained traction with its blockchain technology focused on enhancing communication capabilities between different blockchain networks . As developers strive for seamless asset transfers and application integration, cross-chain interoperability has continued to be a key focus in the crypto industry. As the blockchain infrastructure has developed, LayerZero has been closely monitored by continued ecosystem integrations.

Uniswap Remains a DeFi Market Leader

Uniswap (UNI) have still been functioning as one of the biggest decentralized exchanges in the digital asset arena. Overall trading activity in the decentralized finance sector has been a key gauge for participation and is still playing an active role. While market conditions fluctuate, analysts have observed that the platform’s interest remains high with its protocol improvements and the ongoing governance discussions.

SPX6900 Gains Visibility Among Speculative Assets

SPX6900 (SPX) has remained one of several community-driven digital assets receiving increased attention during recent market activity. Although volatility has remained significantly higher than many established cryptocurrencies, trading interest has continued expanding as investors monitor speculative opportunities alongside larger blockchain projects. Market observers have continued emphasizing that risk management remains essential when evaluating highly volatile assets.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23